Poly (ADP-ribose) polymerase (PARP) inhibition in cancer: Potential impact in cancer stem cells and therapeutic implications

Inhibitors of poly(ADP-ribose) polymerase (PARP) are used in mono- or combination therapies for several malignancies. They are also used as maintenance therapy for some cancers after initial treatment. While the focus of this therapeutic approach is on the effect of PARP inhibition on the bulk tumou...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmacology 2021-11, Vol.911, p.174546, Article 174546
Hauptverfasser: Rizvi, Asim, Merlin, Marine A., Shah, Girish M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 174546
container_title European journal of pharmacology
container_volume 911
creator Rizvi, Asim
Merlin, Marine A.
Shah, Girish M.
description Inhibitors of poly(ADP-ribose) polymerase (PARP) are used in mono- or combination therapies for several malignancies. They are also used as maintenance therapy for some cancers after initial treatment. While the focus of this therapeutic approach is on the effect of PARP inhibition on the bulk tumour cells, in this review, we discuss their effect on the cancer stem cells. We identify key mediators and pathways in cancer stem cells whose response to PARP inhibition is not necessarily the same as the rest of the tumour cells. Since the cancer stem cells are known drivers of growth of tumours and their resistance to therapy, the clinical outcome might be drastically different than what is expected, if the effect of PARP inhibition on the cancer stem cells is not taken into account.
doi_str_mv 10.1016/j.ejphar.2021.174546
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2579088619</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299921007020</els_id><sourcerecordid>2579088619</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-4b9bce0bf4867696742a8cdd7e7dcb97e422c7957d23d6b6046caf35e1ee57b93</originalsourceid><addsrcrecordid>eNp9kEtr3DAURkVoSaZJ_kEIWk4WnkqyLFlZFIb0CYGY0K6FHncYDX5F0hQC_fGxcdLuutJFOve7ugehK0o2lFDx8bCBw7g3ccMIoxsqecXFCVrRWqqCSMreoRUhlBdMKXWGPqR0IIRUilWn6KzkghBF5Ar9aYb2Ga-3n5siBjskuMHjdNNBNAnwutk-Njc49PtgQw5DP5XYmd5BvMXNkKHPwbQ4dKNx-d8bThk67KBtEza9x3k_xY1wzMHNbBucmcPSBXq_M22Cy9fzHP36-uXn3ffi_uHbj7vtfeFKwXLBrbIOiN3xWkihhOTM1M57CdI7qyRwxpxUlfSs9MIKwoUzu7ICClBJq8pztF5yxzg8HSFl3YU0f8_0MByTZpVUpK4FnVG-oC4OKUXY6TGGzsRnTYmeveuDXrzr2btevE9t168TjrYD_7fpTfQEfFoAmPb8HSDq5AJMsnyI4LL2Q_j_hBcJYJaO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2579088619</pqid></control><display><type>article</type><title>Poly (ADP-ribose) polymerase (PARP) inhibition in cancer: Potential impact in cancer stem cells and therapeutic implications</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Rizvi, Asim ; Merlin, Marine A. ; Shah, Girish M.</creator><creatorcontrib>Rizvi, Asim ; Merlin, Marine A. ; Shah, Girish M.</creatorcontrib><description>Inhibitors of poly(ADP-ribose) polymerase (PARP) are used in mono- or combination therapies for several malignancies. They are also used as maintenance therapy for some cancers after initial treatment. While the focus of this therapeutic approach is on the effect of PARP inhibition on the bulk tumour cells, in this review, we discuss their effect on the cancer stem cells. We identify key mediators and pathways in cancer stem cells whose response to PARP inhibition is not necessarily the same as the rest of the tumour cells. Since the cancer stem cells are known drivers of growth of tumours and their resistance to therapy, the clinical outcome might be drastically different than what is expected, if the effect of PARP inhibition on the cancer stem cells is not taken into account.</description><identifier>ISSN: 0014-2999</identifier><identifier>ISSN: 1879-0712</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/j.ejphar.2021.174546</identifier><identifier>PMID: 34600907</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Cancer stem cells ; Cancer therapy ; Cell death ; Differentiation ; Humans ; Neoplasms - drug therapy ; Neoplasms - pathology ; Neoplastic Stem Cells - drug effects ; Neoplastic Stem Cells - pathology ; PARP ; PARP-Inhibitors (PARPi) ; Poly(ADP-ribose) Polymerase Inhibitors - pharmacology ; Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use ; Poly(ADP-ribose) Polymerases - metabolism</subject><ispartof>European journal of pharmacology, 2021-11, Vol.911, p.174546, Article 174546</ispartof><rights>2021 Elsevier B.V.</rights><rights>Copyright © 2021 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-4b9bce0bf4867696742a8cdd7e7dcb97e422c7957d23d6b6046caf35e1ee57b93</citedby><cites>FETCH-LOGICAL-c362t-4b9bce0bf4867696742a8cdd7e7dcb97e422c7957d23d6b6046caf35e1ee57b93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejphar.2021.174546$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27925,27926,45996</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34600907$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rizvi, Asim</creatorcontrib><creatorcontrib>Merlin, Marine A.</creatorcontrib><creatorcontrib>Shah, Girish M.</creatorcontrib><title>Poly (ADP-ribose) polymerase (PARP) inhibition in cancer: Potential impact in cancer stem cells and therapeutic implications</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Inhibitors of poly(ADP-ribose) polymerase (PARP) are used in mono- or combination therapies for several malignancies. They are also used as maintenance therapy for some cancers after initial treatment. While the focus of this therapeutic approach is on the effect of PARP inhibition on the bulk tumour cells, in this review, we discuss their effect on the cancer stem cells. We identify key mediators and pathways in cancer stem cells whose response to PARP inhibition is not necessarily the same as the rest of the tumour cells. Since the cancer stem cells are known drivers of growth of tumours and their resistance to therapy, the clinical outcome might be drastically different than what is expected, if the effect of PARP inhibition on the cancer stem cells is not taken into account.</description><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer stem cells</subject><subject>Cancer therapy</subject><subject>Cell death</subject><subject>Differentiation</subject><subject>Humans</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - pathology</subject><subject>Neoplastic Stem Cells - drug effects</subject><subject>Neoplastic Stem Cells - pathology</subject><subject>PARP</subject><subject>PARP-Inhibitors (PARPi)</subject><subject>Poly(ADP-ribose) Polymerase Inhibitors - pharmacology</subject><subject>Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use</subject><subject>Poly(ADP-ribose) Polymerases - metabolism</subject><issn>0014-2999</issn><issn>1879-0712</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtr3DAURkVoSaZJ_kEIWk4WnkqyLFlZFIb0CYGY0K6FHncYDX5F0hQC_fGxcdLuutJFOve7ugehK0o2lFDx8bCBw7g3ccMIoxsqecXFCVrRWqqCSMreoRUhlBdMKXWGPqR0IIRUilWn6KzkghBF5Ar9aYb2Ga-3n5siBjskuMHjdNNBNAnwutk-Njc49PtgQw5DP5XYmd5BvMXNkKHPwbQ4dKNx-d8bThk67KBtEza9x3k_xY1wzMHNbBucmcPSBXq_M22Cy9fzHP36-uXn3ffi_uHbj7vtfeFKwXLBrbIOiN3xWkihhOTM1M57CdI7qyRwxpxUlfSs9MIKwoUzu7ICClBJq8pztF5yxzg8HSFl3YU0f8_0MByTZpVUpK4FnVG-oC4OKUXY6TGGzsRnTYmeveuDXrzr2btevE9t168TjrYD_7fpTfQEfFoAmPb8HSDq5AJMsnyI4LL2Q_j_hBcJYJaO</recordid><startdate>20211115</startdate><enddate>20211115</enddate><creator>Rizvi, Asim</creator><creator>Merlin, Marine A.</creator><creator>Shah, Girish M.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20211115</creationdate><title>Poly (ADP-ribose) polymerase (PARP) inhibition in cancer: Potential impact in cancer stem cells and therapeutic implications</title><author>Rizvi, Asim ; Merlin, Marine A. ; Shah, Girish M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-4b9bce0bf4867696742a8cdd7e7dcb97e422c7957d23d6b6046caf35e1ee57b93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer stem cells</topic><topic>Cancer therapy</topic><topic>Cell death</topic><topic>Differentiation</topic><topic>Humans</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - pathology</topic><topic>Neoplastic Stem Cells - drug effects</topic><topic>Neoplastic Stem Cells - pathology</topic><topic>PARP</topic><topic>PARP-Inhibitors (PARPi)</topic><topic>Poly(ADP-ribose) Polymerase Inhibitors - pharmacology</topic><topic>Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use</topic><topic>Poly(ADP-ribose) Polymerases - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rizvi, Asim</creatorcontrib><creatorcontrib>Merlin, Marine A.</creatorcontrib><creatorcontrib>Shah, Girish M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rizvi, Asim</au><au>Merlin, Marine A.</au><au>Shah, Girish M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Poly (ADP-ribose) polymerase (PARP) inhibition in cancer: Potential impact in cancer stem cells and therapeutic implications</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2021-11-15</date><risdate>2021</risdate><volume>911</volume><spage>174546</spage><pages>174546-</pages><artnum>174546</artnum><issn>0014-2999</issn><issn>1879-0712</issn><eissn>1879-0712</eissn><abstract>Inhibitors of poly(ADP-ribose) polymerase (PARP) are used in mono- or combination therapies for several malignancies. They are also used as maintenance therapy for some cancers after initial treatment. While the focus of this therapeutic approach is on the effect of PARP inhibition on the bulk tumour cells, in this review, we discuss their effect on the cancer stem cells. We identify key mediators and pathways in cancer stem cells whose response to PARP inhibition is not necessarily the same as the rest of the tumour cells. Since the cancer stem cells are known drivers of growth of tumours and their resistance to therapy, the clinical outcome might be drastically different than what is expected, if the effect of PARP inhibition on the cancer stem cells is not taken into account.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>34600907</pmid><doi>10.1016/j.ejphar.2021.174546</doi></addata></record>
fulltext fulltext
identifier ISSN: 0014-2999
ispartof European journal of pharmacology, 2021-11, Vol.911, p.174546, Article 174546
issn 0014-2999
1879-0712
1879-0712
language eng
recordid cdi_proquest_miscellaneous_2579088619
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Animals
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Cancer stem cells
Cancer therapy
Cell death
Differentiation
Humans
Neoplasms - drug therapy
Neoplasms - pathology
Neoplastic Stem Cells - drug effects
Neoplastic Stem Cells - pathology
PARP
PARP-Inhibitors (PARPi)
Poly(ADP-ribose) Polymerase Inhibitors - pharmacology
Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use
Poly(ADP-ribose) Polymerases - metabolism
title Poly (ADP-ribose) polymerase (PARP) inhibition in cancer: Potential impact in cancer stem cells and therapeutic implications
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T13%3A59%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Poly%20(ADP-ribose)%20polymerase%20(PARP)%20inhibition%20in%20cancer:%20Potential%20impact%20in%20cancer%20stem%20cells%20and%20therapeutic%20implications&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Rizvi,%20Asim&rft.date=2021-11-15&rft.volume=911&rft.spage=174546&rft.pages=174546-&rft.artnum=174546&rft.issn=0014-2999&rft.eissn=1879-0712&rft_id=info:doi/10.1016/j.ejphar.2021.174546&rft_dat=%3Cproquest_cross%3E2579088619%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2579088619&rft_id=info:pmid/34600907&rft_els_id=S0014299921007020&rfr_iscdi=true